Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Neuroethics Guiding Principles for the NIH BRAIN Initiative.

Greely HT, Grady C, Ramos KM, Chiong W, Eberwine J, Farahany NA, Johnson LSM, Hyman BT, Hyman SE, Rommelfanger KS, Serrano EE.

J Neurosci. 2018 Dec 12;38(50):10586-10588. doi: 10.1523/JNEUROSCI.2077-18.2018. No abstract available.

2.

Neuroethics Questions to Guide Ethical Research in the International Brain Initiatives.

Global Neuroethics Summit Delegates, Rommelfanger KS, Jeong SJ, Ema A, Fukushi T, Kasai K, Ramos KM, Salles A, Singh I.

Neuron. 2018 Oct 10;100(1):19-36. doi: 10.1016/j.neuron.2018.09.021. Review.

PMID:
30308169
3.

Ethical principles for the use of human cellular biotechnologies.

Wolpe PR, Rommelfanger KS; Drafting and Reviewing Delegates of the BEINGS Working Groups.

Nat Biotechnol. 2017 Nov 9;35(11):1050-1058. doi: 10.1038/nbt.4007. No abstract available.

PMID:
29121024
4.

Disentangling Stigma from Functional Neurological Disorders: Conference Report and Roadmap for the Future.

Rommelfanger KS, Factor SA, LaRoche S, Rosen P, Young R, Rapaport MH.

Front Neurol. 2017 Mar 29;8:106. doi: 10.3389/fneur.2017.00106. eCollection 2017.

5.

Noradrenergic regulation of plasticity marker expression in the adult rodent piriform cortex.

Vadodaria KC, Yanpallewar SU, Vadhvani M, Toshniwal D, Liles LC, Rommelfanger KS, Weinshenker D, Vaidya VA.

Neurosci Lett. 2017 Mar 22;644:76-82. doi: 10.1016/j.neulet.2017.02.060. Epub 2017 Feb 23.

6.

Biometric Tracking From Professional Athletes to Consumers.

Purcell RH, Rommelfanger KS.

Am J Bioeth. 2017 Jan;17(1):72-74. No abstract available.

PMID:
27996927
7.

The role of placebo in the diagnosis and treatment of functional neurologic disorders.

Rommelfanger KS.

Handb Clin Neurol. 2016;139:607-617. doi: 10.1016/B978-0-12-801772-2.00049-7. Review.

PMID:
27719875
8.

Commentary: Attention to Eyes Is Present but in Decline in 2-6-Month-Old Infants Later Diagnosed with Autism.

Sarrett JC, Rommelfanger KS.

Front Public Health. 2015 Dec 8;3:272. doi: 10.3389/fpubh.2015.00272. eCollection 2015. No abstract available.

9.

Internet-based brain training games, citizen scientists, and big data: ethical issues in unprecedented virtual territories.

Purcell RH, Rommelfanger KS.

Neuron. 2015 Apr 22;86(2):356-9. doi: 10.1016/j.neuron.2015.03.044.

10.

Localization and function of dopamine receptors in the subthalamic nucleus of normal and parkinsonian monkeys.

Galvan A, Hu X, Rommelfanger KS, Pare JF, Khan ZU, Smith Y, Wichmann T.

J Neurophysiol. 2014 Jul 15;112(2):467-79. doi: 10.1152/jn.00849.2013. Epub 2014 Apr 23.

11.

When "I" becomes "We": ethical implications of emerging brain-to-brain interfacing technologies.

Trimper JB, Wolpe PR, Rommelfanger KS.

Front Neuroeng. 2014 Feb 12;7:4. doi: 10.3389/fneng.2014.00004. eCollection 2014. No abstract available.

12.

Guidelines for the ethical use of neuroimages in medical testimony: report of a multidisciplinary consensus conference.

Meltzer CC, Sze G, Rommelfanger KS, Kinlaw K, Banja JD, Wolpe PR.

AJNR Am J Neuroradiol. 2014 Apr;35(4):632-7. doi: 10.3174/ajnr.A3711. Epub 2013 Aug 29.

13.

Opinion: A role for placebo therapy in psychogenic movement disorders.

Rommelfanger KS.

Nat Rev Neurol. 2013 Jun;9(6):351-6. doi: 10.1038/nrneurol.2013.65. Epub 2013 Apr 30. Review.

PMID:
23628738
14.

Selective loss of noradrenaline exacerbates early cognitive dysfunction and synaptic deficits in APP/PS1 mice.

Hammerschmidt T, Kummer MP, Terwel D, Martinez A, Gorji A, Pape HC, Rommelfanger KS, Schroeder JP, Stoll M, Schultze J, Weinshenker D, Heneka MT.

Biol Psychiatry. 2013 Mar 1;73(5):454-63. doi: 10.1016/j.biopsych.2012.06.013. Epub 2012 Aug 9.

15.

Extrastriatal D2-like receptors modulate basal ganglia pathways in normal and Parkinsonian monkeys.

Hadipour-Niktarash A, Rommelfanger KS, Masilamoni GJ, Smith Y, Wichmann T.

J Neurophysiol. 2012 Mar;107(5):1500-12. doi: 10.1152/jn.00348.2011. Epub 2011 Nov 30.

16.

Extrastriatal dopaminergic circuits of the Basal Ganglia.

Rommelfanger KS, Wichmann T.

Front Neuroanat. 2010 Oct 27;4:139. doi: 10.3389/fnana.2010.00139. eCollection 2010.

17.

Light and electron microscopic localization of alpha-1 adrenergic receptor immunoreactivity in the rat striatum and ventral midbrain.

Rommelfanger KS, Mitrano DA, Smith Y, Weinshenker D.

Neuroscience. 2009 Feb 18;158(4):1530-40. doi: 10.1016/j.neuroscience.2008.11.019. Epub 2008 Nov 17.

18.

Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice.

Rommelfanger KS, Edwards GL, Freeman KG, Liles LC, Miller GW, Weinshenker D.

Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13804-9. Epub 2007 Aug 16.

19.

Norepinephrine: The redheaded stepchild of Parkinson's disease.

Rommelfanger KS, Weinshenker D.

Biochem Pharmacol. 2007 Jul 15;74(2):177-90. Epub 2007 Feb 3. Review.

PMID:
17416354
20.

Reduced MPTP toxicity in noradrenaline transporter knockout mice.

Rommelfanger KS, Weinshenker D, Miller GW.

J Neurochem. 2004 Dec;91(5):1116-24.

Supplemental Content

Loading ...
Support Center